# Eli Lilly says its experimental weight-loss shot retatrutide delivered dramatic weight loss in a late-stage study of people with obesity.

*biotech · news · 2026-05-21 · USA TODAY*

## Key points

- Eli Lilly's retatrutide weight-loss shot achieved up to 28% weight loss in late-stage trials.
- Nearly half of participants on the highest dose lost over 30% of body weight, matching surgery outcomes.
- Retatrutide combines GIP, GLP-1, and glucagon receptor agonists, unlike current GLP-1-only drugs.
- Lilly has not yet filed for FDA approval but may do so before the end of this year.

**Companies:** Eli Lilly, Novo Nordisk

[Read the full story on USA TODAY](https://www.usatoday.com/story/money/2026/05/21/retatrutide-weight-loss-shot-eli-lilly/90192588007/)

---

Canonical: https://newsio.io/n/5e9e44b2-a409-43c2-a8b0-1cd51454d7e6/eli-lilly-says-its-experimental-weight-loss-shot-retatrutide-delivered-dramatic
Summarized by Newsio from USA TODAY. https://newsio.io/how-it-works